Table 3

Published risk stratified adjuvant therapy trials for uveal melanoma using molecular techniques

StudyDesignInclusion criteriaEnrolment (N)Median follow-upOutcomes
Adjuvant dendritic cell vaccination in high-risk uveal melanoma (Bol et al 2016)Non-randomised phase II clinical trialHigh-risk chromosome status (monosomy 3)23 patients completed at least one cycle, 18 patients completed all three vaccination cyclesNot reportedMedian DFS 34.5 months (95% CI: 27.2 to 41.8)
Median OS 51.8 months (95% CI :42.1 to 62.7)
Adjuvant sunitinib in high-risk patients with uveal melanoma (Valsecchi et al 2018)Retrospective cohort study1) High-risk chromosome status (monosomy 3 and 8q amplification) or GEP class two or (2) high-risk chromosome status (monosomy 3) and large tumour size (T3-4 AJCC)128 (54 treated patients)Median 52.7 months (range: 0.26–108 months)Median PFS-treated patients 58.6 months (95% CI: 33.1 to 84.1)
5-year OS probability
Sunitinib 0.75 (95% CI: 0.59 to 0.85)
No sunitinib 0.55 (95% CI 0.43 to 0.66)
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes (present study)Non-randomised prospective clinical trialHigh-risk chromosome status (monosomy 3)150 (33 treated patients)Median (for metastasis-free patients still being followed) 63.9 months (range: 1.0–97.5)5-year MFS enrolled 64%±9%, not enrolled 33%±10%
5-year OS 66%±9% enrolled, 37%±10% not enrolled
  • AJCC, American Joint Committee on Cancer; DFS, disease-free survival; GEP, gene expression profiling; MFS, metastasis-free survival; OS, overall survival; PFS, progression-free survival.